TY - JOUR
T1 - Metabolic tumor imaging using magnetic resonance spectroscopy
AU - Glunde, Kristine
AU - Bhujwalla, Zaver M.
N1 - Funding Information:
Supported in part by National Institutes of Health Grants No. R01 CA134695 , P50 CA103175 , R01 CA73850 , R01 CA82337 , R01 CA136576 , R01 CA138515 , R21 CA140904 , and R21 CA133600 .
PY - 2011/2
Y1 - 2011/2
N2 - The adaptability and the genomic plasticity of cancer cells, and the interaction between the tumor microenvironment and co-opted stromal cells, coupled with the ability of cancer cells to colonize distant organs, contribute to the frequent intractability of cancer. It is becoming increasingly evident that personalized molecular targeting is necessary for the successful treatment of this multifaceted and complex disease. Noninvasive imaging modalities such as magnetic resonance (MR), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) are filling several important niches in this era of targeted molecular medicine, in applications that span from bench to bedside. In this review we focus on noninvasive magnetic resonance spectroscopy (MRS) and spectroscopic imaging (MRSI) and their roles in future personalized medicine in cancer. Diagnosis, the identification of the most effective treatment, monitoring treatment delivery, and response to treatment are some of the broad areas into which MRS techniques can be integrated to improve treatment outcomes. The development of novel probes for molecular imagingin combination with a slew of functional imaging capabilitiesmakes MRS techniques, especially in combination with other imaging modalities, valuable in cancer drug discovery and basic cancer research.
AB - The adaptability and the genomic plasticity of cancer cells, and the interaction between the tumor microenvironment and co-opted stromal cells, coupled with the ability of cancer cells to colonize distant organs, contribute to the frequent intractability of cancer. It is becoming increasingly evident that personalized molecular targeting is necessary for the successful treatment of this multifaceted and complex disease. Noninvasive imaging modalities such as magnetic resonance (MR), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) are filling several important niches in this era of targeted molecular medicine, in applications that span from bench to bedside. In this review we focus on noninvasive magnetic resonance spectroscopy (MRS) and spectroscopic imaging (MRSI) and their roles in future personalized medicine in cancer. Diagnosis, the identification of the most effective treatment, monitoring treatment delivery, and response to treatment are some of the broad areas into which MRS techniques can be integrated to improve treatment outcomes. The development of novel probes for molecular imagingin combination with a slew of functional imaging capabilitiesmakes MRS techniques, especially in combination with other imaging modalities, valuable in cancer drug discovery and basic cancer research.
UR - http://www.scopus.com/inward/record.url?scp=79952154676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952154676&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2010.11.001
DO - 10.1053/j.seminoncol.2010.11.001
M3 - Article
C2 - 21362514
AN - SCOPUS:79952154676
SN - 0093-7754
VL - 38
SP - 26
EP - 41
JO - Seminars in oncology
JF - Seminars in oncology
IS - 1
ER -